Avid BioservicesCDMO
CDMO
About: Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Employees: 371
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
65% more capital invested
Capital invested by funds: $469M [Q2] → $772M (+$303M) [Q3]
20% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 49
3.17% more ownership
Funds ownership: 103.45% [Q2] → 106.62% (+3.17%) [Q3]
0% more funds holding
Funds holding: 171 [Q2] → 171 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 25
24% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $1.35M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12.50
2%
upside
Avg. target
$12.50
2%
upside
High target
$12.50
2%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
RBC Capital Sean Dodge 50% 1-year accuracy 21 / 42 met price target | 2%upside $12.50 | Sector Perform Downgraded | 7 Nov 2024 |
Financial journalist opinion
Based on 26 articles about CDMO published over the past 30 days
Neutral
Accesswire
20 hours ago
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
Accesswire
1 day ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
GlobeNewsWire
2 days ago
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has commenced mailing definitive proxy materials and a letter to stockholders in connection with its pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”).
Neutral
Accesswire
2 days ago
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
Neutral
Accesswire
3 days ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
Accesswire
4 days ago
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
Accesswire
5 days ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
Neutral
Accesswire
6 days ago
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Charts implemented using Lightweight Charts™